Posted by Michael Wonder on 04 Jan 2023
Orasis Pharmaceuticals submits new drug application for investigational novel eye drop candidate, CSF-1, for the treatment of presbyopia
3 January 2023 - Phase 3 NEAR-1 and NEAR-2 clinical trials, involving over 600 patients, met primary and key secondary outcomes and serve as the basis for the submission.
Orasis Pharmaceuticals today announced that it has submitted a new drug application to the US FDA for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).
